Anaplastic lymphoma kinase (ALK), epidermal growth factor receptor (EGFR), ROS proto-oncogene 1 (ROS1), and serine/threonine-protein kinase B-Raf (BRAF) inhibitors have become key components of lung cancer therapy. Here, ALK is linked to lung cancer.